A comparative trial of combination therapy in obstructive airways disease.
Eleven patients suffering from chronic reversible airways obstruction completed a comparative crossover trial of two combinations of a controlled-release aminophylline formulation and inhaled salbutamol, and two combinations of oral and inhaled salbutamol. Assessment was by FEV1, which was measured at the end of each 2-week treatment period. The highest mean FEV1 was recorded in patients using controlled-release aminophylline plus routine inhaled salbutamol. The only treatment which gave a significant (p < 0.05) increase over baseline was a combination of controlled-release aminophylline and inhaled salbutamol on demand. The combination of controlled-release aminophylline plus inhaled salbutamol on need was significantly more effective than the combination of oral salbutamol plus routinely inhaled salbutamol.
D000328:Adult; D000368:Aged; D000402:Airway Obstruction / Q000188:drug therapy* / Q000503:physiopathology; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use; D000628:Aminophylline / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000008:administration & dosage
D003692:Delayed-Action Preparations; D000628:Aminophylline; D013806:Theophylline; D000420:Albuterol